Life sciences span a wide range of disciplines that study living organisms in six categories, from molecules and cells to ecosystems and human health. The category that intersects in our world is Applied Life Sciences. And more specifically these fields that translate biological knowledge into practical solutions.
- Biotechnology – using living systems for technology and innovation
- Pharmacology – drug action and development
- Biomedical Science – disease mechanisms, diagnostics, therapeutics
- Stem Cell Biology & Regenerative Medicine – cell-based therapies
In this monthly report you will find news and highlights in the Applied Life Science.
Biotechnology
Clearmind Reaches Key Clinical Trial Milestone as DSMB Unanimously Clears Progression in AUD Study
Clearmind Medicine Inc., a clinical-stage biotechnology company pioneering nonhallucinogenic neuroplastogenderived treatments for AUD, addictions, and weight management, announced that its independent DSMB has unanimously approved advancing the Company’s ongoing FDA-regulated Phase I/II clinical trial to parts B and C (the two of the remaining 3 parts) of the clinical trial, evaluating CMND-100 in patients actively suffering from AUD and in healthy participants, respectively. The DSMB’s approval follows the successful completion of Part A of the study, where CMND-100 achieved its primary safety endpoint, demonstrating a favorable safety and tolerability profile across all planned dose levels in healthy participates. After reviewing the full safety dataset from Part A, the DSMB unanimously recommended advancing the study to Parts B and C in accordance with the previously approved study protocol.
TSI Receives Turkish Regulatory Authorization to Initiate Phase 2 PROMPT-STEMI Trial
Thrombolytic Science, LLC, a clinical-stage biotechnology company developing novel thrombolytic therapies, announced that the Turkish Ministry of Health, through the Turkish Medicines and Medical Devices Agency (TİTCK), has authorized the initiation of PROMPT-STEMI, a Phase 2 clinical trial evaluating TSI’s mutant prourokinase (mproUK)-based sequential fibrinolytic approach in patients with ST-segment elevation myocardial infarction (STEMI).
HEALEY ALS Platform Trial Regimen I Enrolment Completed – Topline Results for NUZ-001 Accelerated to Q2 CY2027
Neurizon® Therapeutics Limited, a late-stage clinical biotechnology company dedicated to advancing innovative treatments for neurodegenerative diseases, is pleased to advise that enrolment has been completed in Regimen I of the Phase 2/3 HEALEY ALS Platform Trial evaluating the Company’s lead investigational therapy NUZ-001 for the treatment of amyotrophic lateral sclerosis (ALS).
Pharmacology
Celonic AG and Leukocare AG Announce Development Collaboration to Support Joint Clients with Complex Biologics and Advanced Drug Product Profiles
Celonic AG, a Swiss-based biologics Contract Development and Manufacturing Organization (CDMO), and Leukocare AG, a provider of drug product development services, announced a collaboration to support biopharmaceutical companies developing increasingly complex biologics.
Biomedical
ProBioGen and VarmX B.V. Announce Collaboration for Advanced Cell Line Development
ProBioGen announced a new collaboration with VarmX B.V. for the development of their second therapeutic Factor X candidate. The partnership will advance VarmX’s innovative Factor X program through cell line development using ProBioGen’s proprietary HEK293 host cell line platform. This collaboration builds upon ProBioGen’s extensive expertise in coagulation factor development, including successful programs with, for example, Factor VII and Factor VIII therapeutics.
Devonian Health Group Receives Health Canada Authorization to Initiate Phase II/III Pediatric Clinical Trial of Thykamine™ for Mild-to-Moderate Atopic Dermatitis in Patients Aged 3 Months to 17 Years
Devonian Health Group Inc., a clinical-stage biopharmaceutical company focused on developing innovative therapies targeting fibro-inflammatory diseases, announced that Health Canada has authorized the Company’s Clinical Trial Application (CTA) to initiate its Phase II/III clinical study evaluating PUR 0110 (Thykamine™) cream for the treatment of mild-to-moderate atopic dermatitis (AD) in pediatric patients.
Catching Cancer Earlier, One Breath at a Time: SpotitEarly Partners with HITLAB to Accelerate Its U.S. Launch
When breast cancer is caught while it is still confined to the breast, the five-year relative survival rate is about 99%. Once it has spread to distant parts of the body, that figure falls to roughly 31%, according to the National Cancer Institute. SpotitEarly is working to move far more patients into that first group with a screening test as simple as breathing into a mask. The multi-cancer early-detection company announced a strategic partnership with HITLAB (Healthcare Innovation and Technology Lab), a globally recognized health-technology research and innovation organization based in New York City, to accelerate its U.S. commercialization and capital development.
AlphaRose Therapeutics Announces “N-of-1” Drug Repurposing Platform for Rare Sanfilippo B Syndrome
AlphaRose Therapeutics, through its drug discovery arm, RareLabs, and researchers from the National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH), announced the publication of a landmark study in the Journal of Personalized Medicine. The paper, titled “Personalized Drug Repurposing Screen Identifies Patient-Specific Therapeutic Candidates for Mucopolysaccharidosis Type IIIB,” validates a new, scalable “N-of-1” drug repurposing platform that identifies treatment candidates uniquely tailored to a patient’s specific genetic profile.
Stem Cell Biology & Regenerative Medicine
Touchlight’s Doggybone™ DNA (dbDNA™) Technology Enables First UK Patient Dosing in Pioneering Personalised Lung Cancer Vaccine Trial
Touchlight, the UK-based, market-leading cell-free DNA provider, marked a significant milestone in personalised cancer treatment as the first UK patient was dosed with a bespoke cancer vaccine manufactured using its proprietary dbDNA technology — in a pioneering early-stage trial for the most common type of lung cancer.
Clinical Studies and Trials
Vaximm AG, an OSR Company, Announces Forthcoming Publication of Cross-Indication Clinical Data for VXM01, Its VEGFR-2-Targeted Cancer Vaccine Platformv
OSR Health, Inc. announced that its subsidiary Vaximm AG has completed the analysis of results from two clinical studies evaluating VXM01, an oral DNA vaccine targeting the vascular endothelial growth factor receptor 2 (VEGFR-2), in patients with recurrent glioblastoma.
Kupando Announces First Patient Dosed in Phase 1 Clinical Study of Lead Candidate KUP101 in Advanced Solid Tumors
Kupando, a pioneering biopharmaceutical company developing a TLR 4/7 agonist that stimulates innate immunity and induces trained immunity for use in oncology and infectious diseases, announced that the first patient has been successfully dosed in its Phase 1 clinical study of its lead drug candidate, KUP101, in patients with advanced solid tumors, specifically focusing on advanced skin tumors.
Mergers & Acquisitions Outlook
Source from PwC, Pharmaceutical and life sciences: US Deals 2026 midyear outlook
Biopharma and Biotech
Deal volume and value: Q1 2026 biopharma deal value >$65B, the strongest quarter since 2020, with 16 $1B+ deals announced.
Strategic drivers:
- LOE cliffs: Big pharma racing to offset an estimated $300B+ of branded revenue at risk this decade, using M&A to refill late‑stage pipelines.
- Therapeutic focus: Cardiometabolic (including GLP‑1), immunology, oncology, radiopharmaceuticals, vaccines, rare neurology, and genetic medicine are hot spots.
- Deal shape: Preference for mid‑cap biotech and bolt‑on platform acquisitions rather than mega‑mergers; many private‑company takeouts and specialty‑pharma scale plays.
AI and geography:
- AI‑enabled R&D is now a core deal consideration, both as an investment thesis and as a synergy lever in acquired pipelines.
- US and European buyers are increasingly tapping China-originated innovative molecules in oncology, immunology, and metabolic disease, adding geopolitical complexity to deal structures.
Medtech
Momentum: Medtech M&A stayed active through H1 2026, following a decade‑high 2025, with disclosed values supported by several scaled transactions.
Focus areas:
- Higher‑growth categories: Cardiovascular, neurostimulation, and ecosystem platforms (connected devices, monitoring, workflow).
- Portfolio reshaping: Carve‑outs, take‑privates, and divestitures as strategics refine focus and PE pursues operational value creation.
Market conditions: Capital‑market pressure and lower equity valuations are catalysts rather than brakes, pushing both strategics and sponsors toward assets with durable growth and defensible positions.
Events
Future BioTech Expo
When: August 19-20, 2026
Where: Houston TX
Event Page
Hashtag: #FBE26
Register for this event.
The Future Biotech Expo is the United States’ dedicated international exhibition and conference for red biotechnology, the science at the intersection of biology and human health. From pharmaceutical innovation and gene therapy to AI driven drug discovery and regenerative medicine, red biotech is rewriting what’s possible in healthcare. #FBE26 exists to accelerate that progress. Held in Houston, Texas, home to the world’s largest medical complex and one of the fastest-growing life sciences ecosystems in the US, Future BioTech Expo brings together the people, ideas, and capital that move the sector forward.
HLTH USA
When: November 15-18, 2026
Where: Las Vegas, NV
Event Page
Register for this event.
HLTH USA brings together professionals from pharma, tech, AI, health systems, and more to showcase healthcare and wellness innovation and how it may transform health. This year’s event will focus on ROI and accelerating goals. The overall goal of the conference is to bring together the healthcare ecosystem while creating “micro-experiences” tailored to participants.
